Business Context and Reporting Period
Company: MiMedx Group, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2009
Status: Development Stage Enterprise
Overview: MiMedx is a biomaterials company operating in the Orthopedics and Spine markets. The company has generated no operating revenue since its inception in November 2006. It operates through two divisions: MiMedx (collagen-fiber based soft-tissue repair) and SpineMedica (hydrogel-based surgical sheets). SpineMedica received FDA 510(k) clearance for its Paradis Vaso Shield product in April 2009.
Key Financial Metrics
| Metric | Six Months Ended Sep 30, 2009 | Six Months Ended Sep 30, 2008 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(6,084,120) | $(6,738,232) |
| Loss Per Share (Basic & Diluted) | $(0.15) | $(0.22) |
| Cash and Cash Equivalents (Sep 30, 2009) | $5,785 | $34,828 (Mar 31, 2009) |
| Net Cash Used in Operating Activities | $(3,658,138) | $(5,075,082) |
| Total Liabilities | $4,826,707 | $1,699,337 (Mar 31, 2009) |
| Convertible Debt (Face Value) | $3,472,000 | $0 |
| Stockholders' Equity | $2,518,279 | $2,156,226 (Mar 31, 2009) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased significantly. Research and Development (R&D) expenses fell 20.9% to $1.72 million, and General and Administrative (G&A) expenses dropped 39.4% to $2.79 million. This was driven by reduced headcount, elimination of bonus accruals, and lower professional fees.
- Financing Activity: The company completed a private placement of 3% Convertible Senior Secured Promissory Notes in June 2009, raising $3.47 million. This contrasts with the prior period where the company had no debt.
- Non-Cash Expenses: Significant non-cash charges impacted the net loss, including a $1.3 million expense for issuing shares to waive registration rights and a $683,000 derivative expense related to a hybrid debt instrument.
- Gain on Settlement: The company recognized a $566,219 gain from the settlement of certain legal payables.
Outlook, Risks, and Management Commentary
- Liquidity Crisis: As of September 30, 2009, cash on hand was approximately $6,000. Management estimates funds are sufficient only through December 2009, assuming no additional fundraising and conversion of a specific promissory note.
- Going Concern: The company explicitly states its ability to continue as a going concern is dependent on securing additional financing to support R&D and obtain regulatory approvals.
- Recent Fundraising: Subsequent to the period end, the company received $600,000 from a new private placement and $300,000 from the sale of intellectual property (Level Orthopedics division assets).
- Risks: Key risks include the inability to raise capital, potential dilution of existing shareholders, failure to obtain FDA approvals, and the need to relinquish valuable rights to products if funding is secured via collaboration.
Investor Verification Checklist
- Cash Runway: Verify the status of the private placement commenced in October 2009 and whether the $600,000 raised is sufficient to extend operations beyond December 2009.
- Debt Conversion: Review the terms of the $3.47 million convertible notes (conversion price $0.50) and the $295,000 hybrid debt instrument to assess potential dilution.
- Derivative Liabilities: Monitor the fair value adjustments of the warrant derivative liability ($609,666) and hybrid debt instrument ($369,055), as fluctuations in stock price directly impact net income.
- Regulatory Milestones: Confirm the commercial launch timeline for the SpineMedica Paradis Vaso Shield product following its April 2009 FDA clearance.
- Asset Sales: Verify the realization of the $250,000 net gain from the October 2009 sale of the Level Orthopedics division assets.